Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says

This article was originally published in SRA

Executive Summary

More time is needed to gauge whether the US Food and Drug Administration's rare pediatric disease priority review voucher program has actually encouraged the development of new treatments, the Government Accountability Office believes. The FDA, however, isn't interested in giving the incentive program any more time to try to prove itself.

Advertisement

Related Content

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
First Generic Approvals Decline For Fourth Straight Year At US FDA
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
Woodcock, Califf Give Thumbs Up To Certain 21st Century Cures Provisions
Rx For Industry: Key Provisions Of The 21st Century Cures Act
US FDA Getting More Money Up Front Under Cures Bill Revisions
Advertisement
UsernamePublicRestriction

Register

PS118565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel